Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Santiago Ponce-Aix"'
Autor:
Edurne Arriola, MD, PhD, José Manuel Trigo, MD, Amparo Sánchez-Gastaldo, MD, Alejandro Navarro, MD, Coral Perez, MD, Leonardo Crama, MD, Santiago Ponce-Aix, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100266- (2022)
Introduction: SCLC is one of the most lethal malignancies. Classically, staging has been performed using a dual classification distinguishing limited from the extensive stage. This study aimed to evaluate the prognostic value of TNM staging in a real
Externí odkaz:
https://doaj.org/article/ee4d170a7bb04b6b9b63698467121349
Autor:
Irene Ferrer, Álvaro Quintanal-Villalonga, Sonia Molina-Pinelo, Jose Manuel Garcia-Heredia, Marco Perez, Rocío Suárez, Santiago Ponce-Aix, Luis Paz-Ares, Amancio Carnero
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 37, Iss 1, Pp 1-13 (2018)
Abstract Background The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increa
Externí odkaz:
https://doaj.org/article/451f9e0e12884c3098af12d99e050c0a
Autor:
Susana Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia, Irene Sansano, Ana Enguita, Alejandro Navarro-Mendivil, Alex Martinez-Marti, Pablo Martinez, Enriqueta Felip
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0121071 (2015)
BackgroundThe increasing incidence and poor outcome associated with MPM requires finding effective treatment for this disease. PD1/PD-L1 pathway plays a central role in tumor immune evasion and appears to be predictive and prognostic marker. PD-L1 is
Externí odkaz:
https://doaj.org/article/94efa7688f654929aaaa25a78d985aa6
Autor:
Ernest Nadal, Mansoor Saleh, Santiago Ponce Aix, Maria Ochoa-de-Olza, Sandip Pravin Patel, Scott Antonia, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T. Estrem, Jiangang Liu, Emin Avsar, Wen Hong Lin, Karim A. Benhadji, Leena Gandhi, Susan C. Guba, Inmaculada Ales Diaz
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non-small cell lung cancer (NSCLC) using galunisertib with nivolu
Externí odkaz:
https://doaj.org/article/f152b1db103e441ba5117026cc7aba88
Autor:
Daneng Li, Yohann Loriot, Adam M. Burgoyne, James M. Cleary, Armando Santoro, Daniel Lin, Santiago Ponce Aix, Ignacio Garrido-Laguna, Ramu Sudhagoni, Xiang Guo, Svetlana Andrianova, Scott Paulson
Publikováno v:
EClinicalMedicine, Vol 67, Iss , Pp 102376- (2024)
Summary: Background: Cabozantinib is approved for previously treated advanced hepatocellular carcinoma (aHCC) and has been investigated in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ). Atezolizumab plus bevacizumab is approv
Externí odkaz:
https://doaj.org/article/4755d3d913804c63b46661b4dce5ecba
Autor:
Zoran Andric, MD, Gabriella Gálffy, MD, Manuel Cobo Dols, MD, Barna Szima, MD, Goran Stojanovic, MD, Marina Petrovic, MD, Enriqueta Felip, MD, David Vicente Baz, MD, Santiago Ponce Aix, MD, Oscar Juan-Vidal, MD, Zsuzsanna Szalai, MD, Gyorgy Losonczy, MD, Antonio Calles Blanco, MD, Reyes Bernabe, MD, Gema García Ledo, MD, Andrés Aguilar Hernández, MD, Klaus Duecker, PhD, Dongli Zhou, PhD, Andreas Schroeder, MD, Guelseren Guezel, MD, Fortunato Ciardiello, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100461- (2023)
Introduction: We present the results of a phase 2a trial of first-line avelumab (anti–programmed death-ligand 1 antibody) plus cetuximab (anti–EGFR antibody) in patients with advanced squamous NSCLC. Methods: Patients with recurrent or metastatic
Externí odkaz:
https://doaj.org/article/283d0b24db6b460b8d6628f029ba7cc0
Autor:
Emily Alouani, Anas Gazzah, Sandrine Mercier, Ratislav Bahleda, Antoine Hollebecque, Jean-Marie Michot, Capucine Baldini, Samy Ammari, Stephane Champiat, Aurelien Marabelle, Sophie Postel-Vinay, Vincent Ribrag, Yohann Loriot, Santiago Ponce Aix, Linda Mahjoubi
Publikováno v:
European Journal of Cancer. 188:1-7
Autor:
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, Giacomo Massa, Giulio Metro, Isabelle Monnet, Patricia Gomez Iranzo, Fabrizio Tabbo, Emilio Bria, Florian Guisier, Damien Vasseur, Colin R. Lindsay, Santiago Ponce-Aix, Sophie Cousin, Fabrizio Citarella, Vincent Fallet, Jose Nicolas Minatta, Anna Eisert, Hortense de Saint Basile, Clarisse Audigier-Valette, Laura Mezquita, Antonio Calles, Giannis Mountzios, Marco Tagliamento, Jordi Remon Masip, Judith Raimbourg, Safae Terrisse, Alessandro Russo, Diego Cortinovis, Philippe Rochigneux, David James Pinato, Alessio Cortellini, Camille Leonce, Anas Gazzah, Maria-Rosa Ghigna, Roberto Ferrara, Filippo Gustavo Dall’Olio, Francesco Passiglia, Vienna Ludovini, Fabrice Barlesi, Enriqueta Felip, David Planchard, Benjamin Besse
Publikováno v:
Scientia
Chemotherapy; Non–small cell lung cancer; RET inhibitors Quimioteràpia; Càncer de pulmó de cèl·lules no petites; Inhibidors de RET Quimioterapia; Cáncer de pulmón de células no pequeñas; Inhibidores de RET Introduction Nearly 1% to 2% of N
Autor:
Fernando López-Ríos, Luis Paz-Ares, Pilar Garrido, Eva M Garrido-Martin, Jose Palacios, Elena Sanchez, Ana Belén Enguita, Javier Ramos-Paradas, Susana Hernández-Prieto, David Lora, Aranzazu Rosado, Tamara Caniego-Casas, Nuria Carrizo, María Teresa Muñoz-Jimenez, Borja Rodriguez, Urbicio Perez-Gonzalez, David Gómez-Sánchez, Irene Ferrer, Santiago Ponce Aix, Ángel Nuñez Buiza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Tumor mutational burden (TMB) is a recently proposed predictive biomarker for immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available assays for TMB determination differ in horizontal coverage, gene content a
Externí odkaz:
https://doaj.org/article/a0e4de9a317e425992c6330eeb6a0581
Autor:
Lauren Seknazi, Arthur Geraud, Vincent Goldschmidt, Capucine Baldini, Stéphane Champiat, Christophe Massard, Sophie Postel-Vinay, Aurelien Marabelle, Rastilav Bahleda, Antoine Hollebecque, Cristina Smolenschi, Anas Gazzah, Jean-Marie Michot, Patricia Martin-Romano, Aurore Vozy, Perrine Vuagnat, François-Xavier Danlos, Arnaud Bayle, Linda Mahjoubi, Barbara Pistilli, Yohann Loriot, Santiago Ponce-Aix, Kaissa Ouali
Publikováno v:
Cancer Research. 83:P2-13
Background: Breast cancer (BC) is the most frequent cancer and the second leading cause of cancer death for women. Although there is a need of new treatments to improve BC outcome, patients with BC are still under-represented in early phase trials, p